Effect of route of administration on the pharmacokinetics of etretinate in the dog. 1988

L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
Department of Clinical Research and Development, Hoffmann-La Roche Inc., Nutley, N.J. 07110.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005050 Etretinate An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic. B10-9359,Ethyl Etrinoate,Ro 10-9359,Ro-10-9359,Tigason,Tigazon,B10 9359,B109359,Etrinoate, Ethyl,Ro 10 9359,Ro 109359,Ro109359
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D014212 Tretinoin An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Retinoic Acid,Vitamin A Acid,Retin-A,Tretinoin Potassium Salt,Tretinoin Sodium Salt,Tretinoin Zinc Salt,Vesanoid,all-trans-Retinoic Acid,beta-all-trans-Retinoic Acid,trans-Retinoic Acid,Acid, Retinoic,Acid, Vitamin A,Acid, all-trans-Retinoic,Acid, beta-all-trans-Retinoic,Acid, trans-Retinoic,Potassium Salt, Tretinoin,Retin A,Salt, Tretinoin Potassium,Salt, Tretinoin Sodium,Salt, Tretinoin Zinc,Sodium Salt, Tretinoin,Zinc Salt, Tretinoin,all trans Retinoic Acid,beta all trans Retinoic Acid,trans Retinoic Acid
D017255 Acitretin An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate. 13-cis-Acitretin,Etretin,Isoetretin,Acitretin, (Z,E,E,E)-Isomer,Isoacitretin,Neotigason,Ro 10-1670,Ro 13-7652,Ro-10-1670,Ro-13-7652,Soriatane,Ro 101670,Ro 137652,Ro101670,Ro137652

Related Publications

L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
January 1984, Drug metabolism and disposition: the biological fate of chemicals,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
January 1989, Drug metabolism and disposition: the biological fate of chemicals,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
December 1974, Cancer research,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
June 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
January 1991, Fundamental & clinical pharmacology,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
January 2020, Open life sciences,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
December 1983, Journal of pharmacokinetics and biopharmaceutics,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
February 1998, The Journal of pharmacy and pharmacology,
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
October 2018, Journal of psychopharmacology (Oxford, England),
L D Bornemann, and S Cotler, and K C Khoo, and J J Carbone, and W A Colburn
March 1992, Methods and findings in experimental and clinical pharmacology,
Copied contents to your clipboard!